TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06715319
Drug: OCA
Normalized name: DOCA
DrugBank: Desoxycorticosterone acetate (DB06780)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCA 5 mg once daily in combination with UDCA for 12 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
Study: NCT06715319
Drug: UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13\~15 mg/kg/day
Study: NCT06717204
Drug: Vericiguat Oral Tablet [Verquvo]
Normalized name: vericiguat Oral Tablet [Verquvo]
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vericiguat in addition to conventional treatment
Study: NCT04666792
Drug: PrEP
Normalized name: X-Prep
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
Study: NCT04861584
Drug: Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
Normalized name: Toripalimab
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 cycle neoadjuvant therapy and radical cystectomy
Study: NCT05056896
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule taken orally
Study: NCT05849597
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h.
Study: NCT05849597
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h.
Study: NCT05431595
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by Vein (IV)
Study: NCT05431595
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by Vein (IV)
Study: NCT05431595
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by Vein (IV)
Study: NCT05420948
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
Study: NCT05420948
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A chemotherapy drug used to treat cancer.
Study: NCT05420948
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A chemotherapy drug used to treat cancer.
Study: NCT06520397
Drug: Ustekinumab and Upadacitinib
Normalized name: Upadacitinib
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in this group will maintain the original Ustekinumab regimen, receiving 90 mg administered subcutaneously every 8 weeks. In addition, they will receive Upadacitinib administered orally at a dosage of 45 mg daily for 12 weeks. After the 12-week period, the dosage of Upadacitinib will be adjusted based on patient condition and clinical judgment, continuing until the evaluation at week 16. Clinical efficacy of the dual-target therapy will be evaluated at week 16.
Study: NCT06520397
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive an additional induction dose of Ustekinumab administered intravenously at 6 mg/kg at baseline. This will be followed by subcutaneous maintenance therapy of 90 mg every 4 weeks. Clinical efficacy will be evaluated at week 16.
Study: NCT06154018
Drug: Protamin
Normalized name: Protamina
DrugBank: Protamine sulfate (DB09141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
Study: NCT06362005
Drug: Triamcinolone Acetonide 0.1% Oint
Normalized name: TRIAMCINOLONE ACETONIDE 0.1% OINT
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RCT
Study: NCT06362005
Drug: Selenium
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT
Study: NCT06362005
Drug: Selenium & Triamcinolone Acetonide 0.1% Oint
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RCT
Study: NCT06362005
Drug: Selenium& Tacrollimus topical
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT
Study: NCT05980598
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
Study: NCT06218823
Drug: Transdermal Nicotine Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a stop smoking aid, 21 milligrams(mg), 14mg, or 7mg of nicotine delivered over 24 hours
Study: NCT06218823
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of an oral smoking cessation medication
Study: NCT05912621
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
Study: NCT06225115
Drug: KYN-5356
Normalized name: L-4-CL-KYN
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KYN-5356, oral tablet
Study: NCT06354673
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous Dexmedetomidine infusion
Study: NCT06354673
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous ketamine infusion
Study: NCT05604261
Drug: Anaprazole sodium 40 mg
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study: NCT05604261
Drug: Anaprazole sodium 60 mg
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study: NCT05604261
Drug: Rabeprazole sodium 20 mg
Normalized name: rabeprazole sodium 20 MG
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study: NCT04708886
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Year 1 study drug
Study: NCT04708886
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Year 2 study drug
Study: NCT05323890
Drug: Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
Study: NCT06551220
Drug: Trastuzumab Deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
Study: NCT05759949
Drug: RLY-5836
Normalized name: RLY-2608
DrugBank: RLY-2608 (DB16751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.
Study: NCT05759949
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.
Study: NCT06102395
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
Study: NCT06102395
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
Study: NCT06102395
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
Study: NCT06102395
Drug: Nedaplatin
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
Study: NCT06102395
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
Study: NCT06102395
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
Study: NCT06102395
Drug: Liposomal paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
Study: NCT00240851
Drug: acetaminophen extended release
Normalized name: acetaminophen Extended Release Oral Tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05365100
Drug: BN102
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablets: BN102, BID
Study: NCT05068453
Drug: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
Normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OH2：less than 8mL/time，Q2W，i.t.；
Study: NCT05068453
Drug: Recombinant humanized anti-PD-1 monoclonal antibody for injection
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HX-008：200mg/time，Q3W，i.v.；
Study: NCT04186585
Drug: BP-C2
Normalized name: Gentamicin C2
DrugBank: Gentamicin C2 (DB17884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily intake
Study: NCT04844125
Drug: SHR-1209
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1209
Study: NCT04949009
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
Study: NCT05804721
Drug: Apipe (Aripiprazole10 mg)
Normalized name: aripiprazole 15 MG
DrugBank: Pentapiperium (DB19383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT05804721
Drug: Abilify (Aripiprazole10 mg)
Normalized name: aripiprazole 10 MG [Abilify]
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference drug
Study: NCT06279611
Drug: LY007
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FC and LY007 infusion
Study: NCT05957042
Drug: Lumason
Normalized name: Lumason
DrugBank: Sulfur hexafluoride (DB11104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 4.8mL administered intravenously
Study: NCT05453214
Drug: Fludrocortisone Acetate 0.1 MG
Normalized name: fludrocortisone acetate 0.1 MG
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
Study: NCT05792917
Drug: tafolecimab (a modified manufacturing process)
Normalized name: Allogeneic processed thymus tissue
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg，SC，single dose
Study: NCT05792917
Drug: tafolecimab (a original manufacturing process)
Normalized name: A+D Original
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg，SC，single dose
Study: NCT05751759
Drug: Mitiperstat
Normalized name: Mitiperstat
DrugBank: Mitiperstat (DB18963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive mitiperstat orally.
Study: NCT04716894
Drug: BI 474121
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 474121 oral solution
Study: NCT04716894
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution
Study: NCT05285891
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two 300 mg intravenous (IV) OCR infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg OCR infusions every 6 months from Month 6 through Month 48.
Study: NCT05285891
Drug: Placebo for Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo infusions every 6 months from Month 30 through Month 48.
Study: NCT06415487
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting agent
Study: NCT06415487
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immune checkpoint anti-PD-1 antibody
Study: NCT06561347
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor
Study: NCT06561347
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent
Study: NCT06561347
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody
Study: NCT04206761
Drug: High Dose Dual Therapy (ICS/LABA)
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
Study: NCT06603558
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05574881
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg qd
Study: NCT05574881
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg d1, 15, 29, and then q4w
Study: NCT05574881
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840mg q3w, and then 420 mg q3w
Study: NCT05574881
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg q3w, and then 6 mg/kg q3w
Study: NCT06629389
Drug: Cannabidiol 100 mg/ml
Normalized name: cannabidiol 100 MG/ML
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study: NCT06629389
Drug: cannabidiol 300 mg/ml
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study: NCT06629389
Drug: Cannabidiol 400 mg/ml
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study: NCT06717100
Drug: Nintedanib 150 MG [Ofev]
Normalized name: nintedanib 150 MG [Ofev]
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
Study: NCT06717711
Drug: PDE5 inhibitor (tadalafil)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphodiesterase-5 (PDE5) inhibitors
Study: NCT06718205
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W
Study: NCT06718205
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD
Study: NCT06718205
Drug: Paclitaxel-albumin
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle
Study: NCT06718205
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle
Study: NCT06718751
Drug: Tranexamic Acid 650 MG
Normalized name: tranexamic acid 650 MG
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO administration of TXA tablet
Study: NCT06719336
Drug: atezolizumab or durvalumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W
Study: NCT05759949
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study: NCT05759949
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study: NCT05759949
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.
Study: NCT05188638
Drug: SoftOx Inhaled Solution (SIS)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
Study: NCT04106115
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg IV infusion every 4 weeks for up to 7 doses